Onconova Therapeutics Inc logo

ONTX - Onconova Therapeutics Inc Share Price

$0.464 -0.0  -7.6%

Last Trade - 9:00pm

Small Cap
Market Cap £67.4m
Enterprise Value £42.7m
Revenue £1.73m
Position in Universe 4229th / 6315
Unlock ONTX Revenue
Relative Strength (%)
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Financial Summary
FINANCIAL BRIEF: : For the three months ended 31 March 2020, Onconova Therapeutics Inc revenues decreased 24% to $52K. Net loss decreased 33% to $5.1M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects General And Administrative a decrease of 35% to $1.8M (expense), Research and development decrease of 16% to $3.3M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


ONTX Revenue Unlock ONTX Revenue

Net Income

ONTX Net Income Unlock ONTX Revenue

Normalised EPS

ONTX Normalised EPS Unlock ONTX Revenue

PE Ratio Range

ONTX PE Ratio Range Unlock ONTX Revenue

Dividend Yield Range

ONTX Dividend Yield Range Unlock ONTX Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ONTX EPS Forecasts Unlock ONTX Revenue
Profile Summary

Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells. It has over three clinical-stage product candidates and various preclinical programs that target kinases, cellular metabolism or cell division in preclinical development. The Company's lead product candidate, rigosertib, is being tested in both intravenous (IV) and oral formulations as a single agent, and the oral formulation is also being tested in combination with azacitidine, in clinical trials for patients with myelodysplastic syndromes (MDS), and related cancers. Its other product candidates include Briciclib and Recilisib.

Last Annual December 31st, 2019
Last Interim March 31st, 2020
Incorporated December 22, 1998
Public Since July 25, 2013
No. of Shareholders: n/a
No. of Employees: 25
Sector Healthcare
Industry Pharmaceuticals
Index Nasdaq Composite ,
Exchange NASDAQ Capital Market
Shares in Issue 168,666,070
Free Float (0.0%)
Eligible for
ONTX Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for ONTX
Upcoming Events for ONTX
Frequently Asked Questions for Onconova Therapeutics Inc
What is the Onconova Therapeutics Inc share price?

As of 9:00pm, shares in Onconova Therapeutics Inc are trading at $0.464, giving the company a market capitalisation of £67.4m. This share price information is delayed by 15 minutes.

How has the Onconova Therapeutics Inc share price performed this year?

Shares in Onconova Therapeutics Inc are currently trading at $0.464 and the price has moved by -84.47% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Onconova Therapeutics Inc price has moved by -85.76% over the past year.

What are the analyst and broker recommendations for Onconova Therapeutics Inc?

Of the analysts with advisory recommendations for Onconova Therapeutics Inc, there are there are currently 0 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Onconova Therapeutics Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Onconova Therapeutics Inc next release its financial results?

Onconova Therapeutics Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-03-31
What is the Onconova Therapeutics Inc dividend yield?

Onconova Therapeutics Inc does not currently pay a dividend.

Does Onconova Therapeutics Inc pay a dividend?

Onconova Therapeutics Inc does not currently pay a dividend.

When does Onconova Therapeutics Inc next pay dividends?

Onconova Therapeutics Inc does not currently pay a dividend.

How do I buy Onconova Therapeutics Inc shares?

To buy shares in Onconova Therapeutics Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Onconova Therapeutics Inc?

Shares in Onconova Therapeutics Inc are currently trading at $0.464, giving the company a market capitalisation of £67.4m.

Where are Onconova Therapeutics Inc shares listed? Where are Onconova Therapeutics Inc shares listed?

Here are the trading details for Onconova Therapeutics Inc:

Country of listing: United States
Exchange: NAQ
Ticker Symbol: ONTX
What kind of share is Onconova Therapeutics Inc?

Based on an overall assessment of its quality, value and momentum, Onconova Therapeutics Inc is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Onconova Therapeutics Inc share price forecast 2020?

Shares in Onconova Therapeutics Inc are currently priced at $0.464. At that level they are trading at 0.227% discount to the analyst consensus target price of 0.00.

Analysts covering Onconova Therapeutics Inc currently have a consensus Earnings Per Share (EPS) forecast of -0.117 for the next financial year.

How can I tell whether the Onconova Therapeutics Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Onconova Therapeutics Inc. Over the past six months, the relative strength of its shares against the market has been 76.75%. At the current price of $0.464, shares in Onconova Therapeutics Inc are trading at -26.4% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Onconova Therapeutics Inc PE Ratio?

We were not able to find PE ratio data for Onconova Therapeutics Inc.

Who are the key directors of Onconova Therapeutics Inc?

Onconova Therapeutics Inc's management team is headed by:

Michael Hoffman - CHM
Abraham Oler - VPR
Henry Bienen - DRC
Manoj Maniar - SVP
Mark Guerin - CFO
Jerome Groopman - DRC
Viren Mehta - DRC
Steven Fruchtman - PRE
E. Premkumar Reddy - DRC
Jack Stover - DRC
Who are the major shareholders of Onconova Therapeutics Inc?

Here are the top five shareholders of Onconova Therapeutics Inc based on the size of their shareholding:

Armistice Capital LLC Hedge Fund
Percentage owned: 4.32% (7.29m shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 1.37% (2.30m shares)
Vanguard Total Stock Market Index Fund Mutual Fund
Percentage owned: 0.8% (1.35m shares)
Susquehanna International Group, LLP Investment Advisor
Percentage owned: 0.66% (1.11m shares)
Vanguard Extended Market Index Fund Mutual Fund
Percentage owned: 0.56% (944k shares)
Similar to ONTX
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.